The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs c
March 6, 2025
The telehealth and telecare industries are experiencing unprecedented transformations driven by shifts in leadership, rapid technological advancements, and ongoing legal challenges. These elements are collectively redefining the landscape of healthcare delivery, compelling companies to adapt and
February 17, 2025
Fosun Pharmaceutical, a leading Chinese pharmaceutical conglomerate, recently attempted to take full control of its biopharma subsidiary, Henlius Biotech, by purchasing the remaining minority shares. This strategic move aimed to consolidate Henlius under Fosun's complete ownership, leveraging
February 12, 2025
The Contract Development and Manufacturing Organization (CDMO) sector is navigating a landscape marked by significant changes and evolving trends. Gil Roth, President of the Pharma & Biopharma Outsourcing Association, provides a comprehensive analysis of the sector's current state and
February 10, 2025
The healthcare investment landscape has undergone significant transformations in recent years, driven by various factors including the COVID-19 pandemic, technological advancements, and strategic shifts within the industry. As we delve into 2024, it is crucial to understand the key trends and
February 7, 2025
In a groundbreaking development, the recent trials of a drug developed by Ireland-based psychedelics biotech company GH Research have showcased its potential in treating treatment-resistant depression. The mid-stage clinical trial, comprising 81 participants, revealed a significant reduction in
February 7, 2025
